| One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α-and β-cell function and reduces … KB Degn, CB Juhl, J Sturis, G Jakobsen, B Brock, V Chandramouli, ... diabetes 53 (5), 1187-1194, 2004 | 597 | 2004 |
| In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial M Gejl, A Gjedde, L Egefjord, A Møller, SB Hansen, K Vang, A Rodell, ... Frontiers in aging neuroscience 8, 198350, 2016 | 405 | 2016 |
| Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia KB Degn, B Brock, CB Juhl, CB Djurhuus, J Grubert, D Kim, J Han, ... Diabetes 53 (9), 2397-2403, 2004 | 350 | 2004 |
| Amylin agonists: a novel approach in the treatment of diabetes O Schmitz, B Brock, J Rungby Diabetes 53 (suppl_3), S233-S238, 2004 | 311 | 2004 |
| Liraglutide, a once‐daily human GLP‐1 analogue, improves pancreatic B‐cell function and arginine‐stimulated insulin secretion during hyperglycaemia in patients with Type 2 … T Vilsbøll, B Brock, H Perrild, K Levin, HH Lervang, K Kølendorf, T Krarup, ... Diabetic Medicine 25 (2), 152-156, 2008 | 298 | 2008 |
| How are medication errors defined? A systematic literature review of definitions and characteristics M Lisby, LP Nielsen, B Brock, J Mainz International Journal for Quality in Health Care 22 (6), 507-518, 2010 | 271 | 2010 |
| Identifying high-risk medication: a systematic literature review EA Saedder, B Brock, LP Nielsen, DK Bonnerup, M Lisby European journal of clinical pharmacology 70, 637-645, 2014 | 191 | 2014 |
| Glucagon‐like peptide‐1: regulation of insulin secretion and therapeutic potential J Gromada, B Brock, O Schmitz, P Rorsman Basic & clinical pharmacology & toxicology 95 (6), 252-262, 2004 | 153 | 2004 |
| Blood-brain glucose transfer in Alzheimer’s disease: effect of GLP-1 analog treatment M Gejl, B Brock, L Egefjord, K Vang, J Rungby, A Gjedde Scientific reports 7 (1), 17490, 2017 | 141 | 2017 |
| Number of drugs most frequently found to be independent risk factors for serious adverse reactions: a systematic literature review EA Saedder, M Lisby, LP Nielsen, DK Bonnerup, B Brock British journal of clinical pharmacology 80 (4), 808-817, 2015 | 125 | 2015 |
| SLC30A3 Responds to Glucose- and Zinc Variations in ß-Cells and Is Critical for Insulin Production and In Vivo Glucose-Metabolism During ß-Cell Stress K Smidt, N Jessen, AB Petersen, A Larsen, N Magnusson, JB Jeppesen, ... PLoS One 4 (5), e5684, 2009 | 117 | 2009 |
| Zinc-transporter genes in human visceral and subcutaneous adipocytes: lean versus obese K Smidt, SB Pedersen, B Brock, O Schmitz, S Fisker, J Bendix, ... Molecular and cellular endocrinology 264 (1-2), 68-73, 2007 | 116 | 2007 |
| Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on β-cell function in normal living conditions A Mari, K Degn, B Brock, J Rungby, ELE Ferrannini, O Schmitz Diabetes Care 30 (8), 2032-2033, 2007 | 115 | 2007 |
| Capillary dysfunction is associated with symptom severity and neurodegeneration in Alzheimer's disease RB Nielsen, L Egefjord, H Angleys, K Mouridsen, M Gejl, A Møller, ... Alzheimer's & dementia 13 (10), 1143-1153, 2017 | 106 | 2017 |
| The effect of systematic medication review in elderly patients admitted to an acute ward of internal medicine M Lisby, A Thomsen, LP Nielsen, NM Lyhne, C Breum‐Leer, U Fredberg, ... Basic & clinical pharmacology & toxicology 106 (5), 422-427, 2010 | 95 | 2010 |
| Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´ s disease-protocol for a controlled, randomized double-blinded trial. L Egefjord, M Gejl, A Møller, H Brændgaard, H Gottrup, O Antropova, ... brain 12, 14, 2012 | 93 | 2012 |
| Diabetic autonomic neuropathy affects symptom generation and brain-gut axis C Brock, E Søfteland, V Gunterberg, JB Frøkjær, D Lelic, B Brock, ... Diabetes Care 36 (11), 3698-3705, 2013 | 84 | 2013 |
| Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes M Gejl, HM Søndergaard, C Stecher, BM Bibby, N Møller, HE Bøtker, ... The Journal of Clinical Endocrinology & Metabolism 97 (7), E1165-E1169, 2012 | 81 | 2012 |
| Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis S Tarp, D Eric Furst, M Boers, G Luta, H Bliddal, U Tarp, ... Rheumatology 56 (3), 417-425, 2017 | 80 | 2017 |
| Diabetic enteropathy: from molecule to mechanism‐based treatment T Meldgaard, SS Olesen, AD Farmer, K Krogh, AA Wendel, B Brock, ... Journal of diabetes research 2018 (1), 3827301, 2018 | 78 | 2018 |
